392 results match your criteria: "and the Perelman School of Medicine[Affiliation]"

Background: Individuals have a higher risk of cardiovascular disease later in life if they give birth to a child with congenital heart disease (CHD). The mechanism of this association has not been well documented.

Objectives: The authors aimed to describe the prevalence of cardiovascular disease and risk factors in women and birthing individuals 18 to 23 years after delivery of a child with CHD compared to normative data.

View Article and Find Full Text PDF

Reply to: Accurate Determinants of Outcome in ALL.

J Clin Oncol

December 2024

Ti-Cheng Chang, PhD, Center for Applied Bioinformatics, St Jude Children's Research Hospital, Memphis, TN; Wenan Chen, PhD, Center for Applied Bioinformatics, St Jude Children's Research Hospital, Memphis, TN, Division of Computational Biology, Mayo Clinic, Rochester, MN; Chunxu Qu, PhD, Department of Pathology, St Jude Children's Research Hospital, Memphis, TN; Zhongshan Cheng, PhD, Center for Applied Bioinformatics, St Jude Children's Research Hospital, Memphis, TN; Abdelrahman Elsayed, PhD and Stanley B. Pounds, PhD, Department of Biostatistics, St Jude Children's Research Hospital, Memphis, TN; Mary Shago, PhD, Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada; Karen R. Rabin, MD, PhD, Department of Pediatrics, Baylor College of Medicine, Houston, TX; Elizabeth A. Raetz, MD, Department of Pediatrics, Perlmutter Cancer Center, NYU Langone Hospital, New York, NY; Meenakshi Devidas, PhD, Global Pediatric Medicine, St Jude Children's Research Hospital, Memphis, TN; Cheng Cheng, PhD, Department of Biostatistics, St Jude Children's Research Hospital, Memphis, TN; Anne Angiolillo, MD, Children's National Medical Center, Washington, DC; Pradyuamma Baviskar, PhD, Department of Pathology, St Jude Children's Research Hospital, Memphis, TN; Michael Borowitz, MD, Department of Pathology, Johns Hopkins University, Baltimore, MD; Michael J. Burke, MD, Division of Pediatric Hematology-Oncology, Medical College of Wisconsin, Milwaukee, WI; Andrew Carroll, PhD, Department of Genetics, University of Alabama at Birmingham, Birmingham, AL; William L. Carroll, MD, Department of Pediatrics, Perlmutter Cancer Center, NYU Langone Hospital, New York, NY; I-Ming Chen, DVM and Richard Harvey, PhD, Department of Pathology, University of New Mexico, Albuquerque, NM; Nyla Heerema, PhD, The Ohio State University, Columbus, OH; Ilaria Iacobucci, PhD, Department of Pathology, St Jude Children's Research Hospital, Memphis, TN; Jeremy R. Wang, PhD, Department of Genetics, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC; Sima Jeha, MD, Department of Oncology, St Jude Children's Research Hospital, Memphis, TN; Eric Larsen, MD, Department of Pediatrics, Maine Children's Cancer Program, Scarborough, ME; Leonard Mattano, MD, HARP Pharma Consulting, Mystic, CT; Kelly Maloney, MD, Department of Pediatrics and Children's Hospital Colorado, University of Colorado, Aurora, CO; Ching-Hon Pui, MD, Department of Oncology, St Jude Children's Research Hospital, Memphis, TN; Nilsa C. Ramirez, MD, Institute for Genomic Medicine and Biopathology Center, Nationwide Children's Hospital, Departments of Pathology and Pediatrics, Ohio State University, Columbus, OH; Wanda Salzer, MD, Uniformed Services University, School of Medicine, Bethesda, MD; Cheryl Willman, MD, Department of Laboratory Medicine and Pathology and Mayo Clinic Comprehensive Cancer Center, Mayo Clinic, Rochester, MN; Naomi Winick, MD, Department of Pediatric Hematology Oncology and Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX; Brent Wood, MD, Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, University of Southern California, Los Angeles, CA; Stephen P. Hunger, MD, Department of Pediatrics and the Center for Childhood Cancer Research, Children's Hospital of Philadelphia, and the Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA; Gang Wu, PhD, Center for Applied Bioinformatics, St Jude Children's Research Hospital, Memphis, TN, Department of Pathology, St Jude Children's Research Hospital, Memphis, TN; Charles G. Mullighan, MBBS, MD, Department of Pathology, St Jude Children's Research Hospital, Memphis, TN; and Mignon L. Loh, MD, Department of Pediatrics and the Ben Towne Center for Childhood Cancer Research, Seattle Children's Hospital, University of Washington, Seattle, WA.

View Article and Find Full Text PDF

Cornelia de Lange syndrome (CdLS) is a rare, dominantly inherited multisystem developmental disorder. Pathogenic variants in genes encoding the structural subunits and regulatory proteins of the cohesin complex (, , , , and ) are the primary contributors to the pathogenesis of CdLS. Pathogenic variations in these genes disrupt normal cohesin function, leading to the syndrome's diverse and complex clinical presentation.

View Article and Find Full Text PDF

Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children.

N Engl J Med

December 2024

From the Division of Haematology-Oncology (S.G., S.A., S.Z.), the Faculty of Medicine (S.G., S.A.), and the Department of Laboratory Medicine and Pathobiology, University of Toronto (M.S.), Toronto, and British Columbia Children's Hospital, University of British Columbia, Vancouver (A.M.L.) - all in Canada; Seattle Children's Hospital (R.E.R., T.H.-W., M.L.L.), the Ben Towne Center for Childhood Cancer and Blood Disorders Research and the Department of Pediatrics, Fred Hutchinson Cancer Center, University of Washington (R.E.R., M.L.L.), and Adaptive Biotechnologies (I.K.) - all in Seattle; the Department of Biostatistics, Colleges of Medicine, Public Health, and Health Professions, University of Florida, Gainesville (J.A.K., C.W., S.C.); the Division of Pediatric Hematology-Oncology, Texas Children's Cancer and Hematology Center, Baylor College of Medicine, Houston (K.R.R.), Children's Blood and Cancer Center and Dell Children's Medical Center of Central Texas, Austin (H.R.K.), and the Department of Pediatrics, Division of Pediatric Hematology-Oncology, Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas (N.W.) - all in Texas; Servier Pharmaceuticals, Boston (A.L.A.); the Department of Genetics, University of Alabama at Birmingham, Birmingham (A.J.C.); Children's Hospital Colorado and the University of Colorado School of Medicine, Aurora (L.G., M.M.O.); the Division of Pediatric Hematology-Oncology, University of Utah, Primary Children's Hospital, Salt Lake City (J.L.M.); the Children's Oncology Group, Monrovia (O.M.), the Department of Pediatric Hematology-Oncology, MemorialCare Miller Children's and Women's Hospital Long Beach, Long Beach (M.O.), the Department of Pathology and Laboratory Medicine, Children's Hospital of Los Angeles, Los Angeles (B.L.W.), and Amgen, Thousand Oaks (F.Z.) - all in California; the Department of Pediatrics, Emory University School of Medicine, Atlanta (T.P.M.); the Steve and Cindy Rasmussen Institute for Genomic Medicine and the Biopathology Center, Nationwide Children's Hospital (S.C.R.) and the Biopathology Center and Children's Oncology Group Biospecimen Bank, Nationwide Children's Hospital (Y.M., E.W.) - both in Columbus, OH; Amgen Research, Munich, Germany (G.Z.); the Department of Global Pediatric Medicine, St. Jude Children's Research Hospital, Memphis, TN (M.D.); the Department of Pediatrics and the Center for Childhood Cancer Research, Children's Hospital of Philadelphia, and the Perelman School of Medicine, University of Pennsylvania - both in Philadelphia (S.P.H., D.T.T.); and the Department of Pediatrics and Perlmutter Cancer Center, NYU Langone Health, New York (E.A.R.).

Background: B-cell acute lymphoblastic leukemia (B-cell ALL) is the most common childhood cancer. Despite a high overall cure rate, relapsed B-cell ALL remains a leading cause of cancer-related death among children. The addition of the bispecific T-cell engager molecule blinatumomab (an anti-CD19 and anti-CD3 single-chain molecule) to therapy for newly diagnosed standard-risk (as defined by the National Cancer Institute) B-cell ALL in children may improve outcomes.

View Article and Find Full Text PDF
Article Synopsis
  • Invasive aspergillosis (IA) and mucormycosis (IM) significantly affect severely ill patients, prompting the approval of isavuconazonium sulfate for treating these fungal infections in both adults and recently in children.
  • A phase 2 study involved 31 pediatric patients across multiple countries, revealing a 54.8% overall response rate to treatment and a low 6.5% all-cause case fatality at 42 days.
  • Although 93.5% of participants experienced treatment-emergent adverse events (TEAEs), the drug was generally well tolerated, and dosing conformed to safety standards previously established in adult studies.
View Article and Find Full Text PDF

Lessons learned from 20 years of preclinical testing in pediatric cancers.

Pharmacol Ther

December 2024

RTI International, Research Triangle Park, NC, United States of America.

Programs for preclinical testing of targeted cancer agents in murine models of childhood cancers have been supported by the National Cancer Institute (NCI) since 2004. These programs were established to work collaboratively with industry partners to address the paucity of targeted agents for pediatric cancers compared with the large number of agents developed and approved for malignancies primarily affecting adults. The distinctive biology of pediatric cancers and the relatively small numbers of pediatric cancer patients are major challenges for pediatric oncology drug development.

View Article and Find Full Text PDF

The pediatric subspecialty workforce is challenged by shortages and geographic maldistribution of subspecialists. We invited leaders in pediatrics to discuss how the field's vitality and survival can be secured. These leaders presented their own opinions and not the opinion of the society or organization that they are presenting.

View Article and Find Full Text PDF
Article Synopsis
  • Educators want to improve education by helping people learn and work together, especially in health professions.
  • They believe it's important to support everyone from beginners to experts so that everyone can grow.
  • The document gives 12 tips on how to create and keep a community that helps with learning and fits well with what schools want to achieve.
View Article and Find Full Text PDF
Article Synopsis
  • Septal reduction therapy (SRT) significantly improves symptoms for patients with obstructive hypertrophic cardiomyopathy (HCM), but its long-term results and predictors of adverse outcomes still need more study.* -
  • An analysis of data from the SHARE registry revealed that among 1,832 patients who underwent SRT, the 30-day mortality rate was low at 0.4%, and after approximately 6.8 years, rates for HCM-related death, heart failure, and ventricular arrhythmias were relatively low.* -
  • Key findings included that older age at SRT increases risks for HCM death and heart failure outcomes, while female patients showed higher susceptibility to heart failure complications post-treatment.*
View Article and Find Full Text PDF

Molecular Genetics of Pheochromocytoma/Paraganglioma.

Curr Opin Endocr Metab Res

September 2024

Hospital of the University of Pennsylvania, Department of Medical Genetics, and the Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.

Pheochromocytomas and paragangliomas (PPGL) are neuroendocrine tumors which secrete catecholamines, causing cardiovascular compromise. While isolated tumors and locoregional disease can be treated surgically, treatment options for metastatic disease are limited, and no targeted therapies exist. Approximately 25% of PPGL are causatively associated with germline pathogenic variants, which are known risk factors for multifocal and metastatic PPGL.

View Article and Find Full Text PDF

Objective: We linked pharmacy dispensing data to clinical data in the electronic health record (EHR) to (1) identify characteristics associated with adherence to methotrexate (MTX) and (2) determine the association between adherence and disease activity in patients with juvenile idiopathic arthritis (JIA).

Methods: We conducted a single-center retrospective cohort study of incident MTX recipients with JIA treated between January 2016 and September 2023 for ≥12 months. Using pharmacy dispensing data, complemented by EHR data, we estimated adherence using medication possession ratios (MPRs) over the first 365 days of treatment.

View Article and Find Full Text PDF

Context: The adverse skeletal effects of type 1 diabetes (T1D) include deficient bone accrual and lifelong increased fracture risk. The contributors to impaired bone accrual in people with T1D are incompletely understood.

Objective: To determine if urinary calcium excretion is associated with impaired bone accrual in youth with T1D and to characterize the contribution of glycemic control and markers of bone mineral metabolism to urinary calcium excretion.

View Article and Find Full Text PDF

Genomic Determinants of Outcome in Acute Lymphoblastic Leukemia.

J Clin Oncol

October 2024

Department of Pediatrics and the Ben Towne Center for Childhood Cancer Research, Seattle Children's Hospital, University of Washington, Seattle, WA.

Article Synopsis
  • Despite high cure rates for childhood acute lymphoblastic leukemia (ALL), it remains a major cause of cancer-related deaths in children, especially among those initially classified as standard-risk (SR).
  • Researchers analyzed genomic data from over 1,300 children with ALL to identify factors influencing relapse, focusing on comparing patients who relapsed against those who stayed in remission for five years.
  • Findings indicated that specific genomic subtypes and chromosomal alterations significantly affect relapse risk, highlighting the need for detailed genetic analysis to improve risk assessment and treatment strategies in childhood ALL.
View Article and Find Full Text PDF

Patterns of recurrence after radiotherapy for high-risk neuroblastoma: Implications for radiation dose and field.

Radiother Oncol

September 2024

Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA. Electronic address:

Background: Prognosis for patients with high-risk neuroblastoma (HR-NBL) is guarded despite aggressive therapy, and few studies have characterized outcomes after radiotherapy in relation to radiation treatment fields.

Methods: Multi-institutional retrospective cohort of 293 patients with HR-NBL who received autologous stem cell transplant (ASCT) and EBRT between 1997-2021. LRR was defined as recurrence at the primary site or within one nodal echelon beyond disease present at diagnosis.

View Article and Find Full Text PDF

Progesterone for Neurodevelopment in Fetuses With Congenital Heart Defects: A Randomized Clinical Trial.

JAMA Netw Open

May 2024

Department of Biostatistics, Epidemiology, and Informatics, the Perelman School of Medicine, University of Pennsylvania, Philadelphia.

Importance: Neurodevelopmental outcomes for children with congenital heart defects (CHD) have improved minimally over the past 20 years.

Objectives: To assess the feasibility and tolerability of maternal progesterone therapy as well as the magnitude of the effect on neurodevelopment for fetuses with CHD.

Design, Setting, And Participants: This double-blinded individually randomized parallel-group clinical trial of vaginal natural progesterone therapy vs placebo in participants carrying fetuses with CHD was conducted between July 2014 and November 2021 at a quaternary care children's hospital.

View Article and Find Full Text PDF

The Society of Thoracic Surgeons (STS) Congenital Heart Surgery Database (CHSD) continues to be the most comprehensive database of congenital and pediatric cardiothoracic surgical procedures in the world and contains information on 664,210 operations as of June 30, 2023. The 35th harvest of the STS CHSD data was undertaken in Spring 2023, spanning the 4-year period January 1, 2019, through December 31, 2022, and included 144,919 operations performed at 114 participating sites in North America. The harvest analysis was successfully executed by the STS Research and Analytic Center.

View Article and Find Full Text PDF

Enhanced Risk Stratification for Children and Young Adults with B-Cell Acute Lymphoblastic Leukemia: A Children's Oncology Group Report.

Leukemia

April 2024

Department of Biostatistics, Colleges of Medicine, Public Health and Health Professions, University of Florida, Gainesville, FL, USA.

Article Synopsis
  • * A multivariable Cox model was developed using data from over 21,000 patients to predict relapse-free survival (RFS) and establish more precise risk groups through the COG Prognostic Index (PI).
  • * The PI effectively differentiates between low and high relapse risks and identifies specific subgroups within moderate and high-risk patients, potentially guiding more personalized treatment strategies based on their predicted outcomes.
View Article and Find Full Text PDF

Background: The primary objective was to measure the proportion of episodes where care delivery was inconsistent with selected recommendations of a clinical practice guideline (CPG) on fever and neutropenia (FN) management. The influence of site size on CPG-inconsistent care delivery, and association between patient outcomes and CPG-inconsistent care were described.

Methods: This retrospective, multicenter study included patients less than 21 years old with cancer who were at high risk of poor FN outcomes and were previously enrolled to a Children's Oncology Group (COG) study at participating National Cancer Institute Community Oncology Research Program (NCORP) institutions from January 2014 through December 2015.

View Article and Find Full Text PDF

In the first prospective study evaluating circulating tumor DNA (ctDNA) for early cancer detection, Wong, Luo, and colleauges demonstrate the feasibility of liquid biopsy as an augmentation to current surveillance protocols for patients with Li-Fraumeni syndrome, an inherited cancer predisposition associated with high cancer risk in both pediatric and adult populations. Though additional clinical validation in larger cohorts is needed, this research highlights that a multimodal approach is likely necessary to improve the sensitivity of liquid biopsy assays for early cancer detection. See related article by Wong, Lou et al.

View Article and Find Full Text PDF

Conjugated hyperbilirubinemia is associated with increased morbidity and mortality after neonatal heart surgery.

Cardiol Young

May 2024

Division of Cardiothoracic Surgery, Department of Surgery, Children's Hospital of Philadelphia and the Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

Background: Cholestasis characterised by conjugated hyperbilirubinemia is a marker of hepatobiliary dysfunction following neonatal cardiac surgery. We aimed to characterise the incidence of conjugated hyperbilirubinemia following neonatal heart surgery and examine the effect of conjugated hyperbilirubinemia on post-operative morbidity and mortality.

Methods: This was a retrospective study of all neonates who underwent surgery for congenital heart disease (CHD) at our institution between 1/1/2010 and 12/31/2020.

View Article and Find Full Text PDF

Objectives: Pediatric emergence delirium is an undesirable outcome that is understudied. Development of a predictive model is an initial step toward reducing its occurrence. This study aimed to apply machine learning (ML) methods to a large clinical dataset to develop a predictive model for pediatric emergence delirium.

View Article and Find Full Text PDF

Patent ductus arteriosus (PDA) and coarctation of the aorta (CoA) are relatively common congenital heart defects. Pathogenic variants in PRDM6, which encodes a smooth-muscle-cell-specific transcription factor, have now been etiologically associated with non-syndromic PDA. We present three patients with PDA and CoA found to harbor PRDM6 variants, including a novel, likely-pathogenic variant.

View Article and Find Full Text PDF

Creatinine and cystatin-C are recommended for estimating glomerular filtration rate (eGFR) but accuracy is suboptimal. Here, using untargeted metabolomics data, we sought to identify candidate filtration markers for a new targeted assay using a novel approach based on their maximal joint association with measured GFR (mGFR) and with flexibility to consider their biological properties. We analyzed metabolites measured in seven diverse studies encompasing 2,851 participants on the Metabolon H4 platform that had Pearson correlations with log mGFR and used a stepwise approach to develop models to < -0.

View Article and Find Full Text PDF
Article Synopsis
  • Recent studies have shown that while genetics play a role in congenital heart defects (CHD), their exact influence on clinical outcomes is still not fully understood due to complex interactions with other factors.
  • The research employed Bayesian Networks to analyze relationships among genetic data, clinical factors, and demographic information in children with single ventricle CHD.
  • Findings revealed that both genetic variants and clinical factors significantly influence mental development outcomes, and their combined effects can drastically alter the likelihood of positive or negative outcomes.
View Article and Find Full Text PDF